Related Experiment Video

Updated: Apr 30, 2026

Mimicking and Manipulating Pancreatic Acinar-to-Ductal Metaplasia in 3-dimensional Cell Culture
08:16

Mimicking and Manipulating Pancreatic Acinar-to-Ductal Metaplasia in 3-dimensional Cell Culture

Published on: February 11, 2019

8.2K

Oncogenic KRAS signalling in pancreatic cancer

S Eser1, A Schnieke2, G Schneider3

  • 11] Department of Internal Medicine II, Klinikum rechts der Isar, Technische Universität München, Ismaningerstr. 22, 81675 München, Germany [2] German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.

British Journal of Cancer
|April 24, 2014
PubMed

Insights

Pancreatic cancer remains deadly, with poor survival rates. Research focuses on targeting KRAS pathways to find new treatments for pancreatic ductal adenocarcinoma (PDAC).

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis with a 5-year survival rate below 5%.
  • Despite extensive research, current treatments for PDAC have not significantly improved survival rates over the past three decades.
  • Oncogenic KRAS mutations are central to PDAC initiation and progression, but direct targeting of KRAS has proven clinically unsuccessful.

Purpose of the Study:

  • To review recent advancements in understanding oncogenic KRAS signaling in PDAC.
  • To explore potential therapeutic strategies targeting downstream effectors, synthetic lethal interactions, and metabolic alterations driven by KRAS.
  • To identify novel therapeutic targets for improving PDAC treatment outcomes.

Main Methods:

  • Literature review of recent research on KRAS signaling pathways in pancreatic cancer.
  • Analysis of genetic aberrations and molecular mechanisms involved in PDAC development.
  • Discussion of preclinical and clinical findings related to KRAS-driven pathways.

Main Results:

  • KRAS is a key driver in PDAC, but direct inhibition has failed.
  • Research is identifying druggable downstream targets and pathways regulated by mutant KRAS.
  • Emerging strategies focus on KRAS effector pathways, synthetic lethality, and metabolic vulnerabilities.

Conclusions:

  • Targeting KRAS-driven pathways, rather than KRAS itself, offers promising therapeutic avenues for PDAC.
  • Further research into KRAS signaling networks is crucial for developing effective treatments.
  • Novel therapeutic strategies hold potential to improve outcomes for patients with pancreatic cancer.

More Related Videos

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer06:20

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

3.9K
Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line06:24

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line

Published on: April 11, 2025

978

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
5.7K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.1K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

6.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K